IP Library Granted Patent US 7,807,801
Granted Patent B2
US 7,807,801 · App. 10/913,996 · Granted Oct 5, 2010

Oligonucleotide analog and method for treating flavivirus infections

Assignee: AVI BioPharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,801
App. No.
10/913,996
Granted
Oct 5, 2010
Kind
B2
Abstract

A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5′ and 3′ cyclization sequences.

Claims (9)

1. An anti-flaviviral compound composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of the adjacent subunit, and characterized by:

(i) a nuclease-resistant backbone,

(ii) capable of uptake by virus-infected animal cells,

(iii) containing between 8-40 nucleotide bases,

(iv) having a sequence of 8 contiguous bases complementary to the sequence identified by SEQ ID NO:3, and

(v) capable of forming with a flavivirus ssRNA genome containing SEQ ID NO: 3, a heteroduplex structure characterized by a temperature of dissociation of at least 45° C.

2. The compound of claim 1 , wherein the morpholino subunits are joined by phosphorodiamidate linkages, in accordance with the structure:

where Y 1 ═O, Z═O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, amino or alkyl amino, including dialkylamino.

3. The compound of claim 1 , which has the sequence identified as SEQ ID NO:22.

Assignments (2)
CHANGE OF NAME Recorded Nov 21, 2013
From: AVI BIOPHARMA, INC.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 031693/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2004
From: IVERSEN, PATRICK L.; STEIN, DAVID A.
To: AVI BIOPHARMA, INC.
Reel/Frame 015965/0661 →
Continuity (3)
Provisional Application 6049304300 · Aug 5, 2003
Provisional Application 6051200300 · Oct 16, 2003
Related Publication 20050096291A1 · May 5, 2005